Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

First Targeted Treatment Eliminates Rare T-Cell Lymphoma After CAR T

Genomic screening guided use of an FDA-approved anti-CCR4 antibody that cleared the cancer in a single-patient case report.

Image

Overview

  • Mount Sinai investigators report in the New England Journal of Medicine that an anti-CCR4 antibody eradicated a CAR-positive T-cell lymphoma that arose after anti-BCMA CAR T for multiple myeloma.
  • The 51-year-old patient had myeloma remission from CAR T before developing rapidly progressive lymphoma involving skin, blood, and bone marrow.
  • Advanced genetic and immunologic profiling identified FDA-approved options, with anti-CCR4 proving effective in this previously untested context.
  • The patient remains in remission from both multiple myeloma and the secondary lymphoma, according to the case report.
  • Researchers describe this as the first reported targeted therapy success for CAR-positive T-cell lymphoma and emphasize continued monitoring and mechanistic studies.